Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806032 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TACR3 | |
| SCHEMBL7078988 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3TACR3 | |
| SCHEMBL14948183 | 0.86 | S1PR1 (0.42) | — | |
| Hydrochloric Acid SCHEMBL11682217 | 0.83 | TACR3 (0.44) | TACR3 | |
| SCHEMBL13957381 | 0.82 | KCNH2 (0.51) | — | |
| SCHEMBL13389892 | 0.81 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13389894 | 0.81 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11680088 | 0.78 | L3MBTL1 (0.50) | — | |
| SCHEMBL23235646 | 0.77 | GRM2 (0.44) | — | |
| SCHEMBL16838115 | 0.77 | SLC18A3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605621-B1 | Safe and effective detoxification after treating drug addiction, or diseases wherein cocaine is administered | GEORGETOWN UNIVERSITY | 2003-08-12 | — | — | US | disclosed |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| US-6440996-B1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | GEORGETOWN UNIVERSITY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | HAX1, MLX, XDH | SLC6A2 258/4885SLC6A4 631/4885SLC6A3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.